Abstract Title
In vitro sensitivity of soft tissue sarcoma cells to novel anthracyclines
Abstract
The development of drug efflux mediated resistance to Doxorubicin (Dox) is a leading cause of treatment failure in sarcoma and other cancers. In order to overcome this obstacle, new Dox analogs are needed that retain cytotoxicity but are insensitive to drug efflux mediated resistance. In this study, we examined the in vitro drug sensitivity of a panel of sarcoma cell lines to novel Dox analogs. Our results may indicate that CM-GPX-160 will be the most effective in terms of cytotoxicity for the cell lines. Also we suspect that M-GPX-150 will be the least cytotoxic. Preliminary results already indicate this to be true. This work is an important initial step in the development of these compounds as new treatments for drug resistant cancers.
In vitro sensitivity of soft tissue sarcoma cells to novel anthracyclines
The development of drug efflux mediated resistance to Doxorubicin (Dox) is a leading cause of treatment failure in sarcoma and other cancers. In order to overcome this obstacle, new Dox analogs are needed that retain cytotoxicity but are insensitive to drug efflux mediated resistance. In this study, we examined the in vitro drug sensitivity of a panel of sarcoma cell lines to novel Dox analogs. Our results may indicate that CM-GPX-160 will be the most effective in terms of cytotoxicity for the cell lines. Also we suspect that M-GPX-150 will be the least cytotoxic. Preliminary results already indicate this to be true. This work is an important initial step in the development of these compounds as new treatments for drug resistant cancers.